A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
A phase 2 trial of Tabelecleucel in brain and spinal cord tumours, sarcomas and uterine sarcoma, run by Pierre Fabre Medicament, active and no longer recruiting.
Overview
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases is a phase 2 interventional study registered as NCT04554914 by Pierre Fabre Medicament, with 190 participants enrolled, started 2021-07-14 and due to reach its primary completion in 2027-06. Interventions recorded: Tabelecleucel.
Similar pages
not linked directly; found by shared links- TrialSTC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Shares Uterine sarcoma, Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialStudy of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialA Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialA Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialPost-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialA Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Shares Brain and spinal cord tumours (all types) and the tag pipeline.